Treatment of Focal Brain Ischemia with Viral Vector-Mediated Gene Transfer

Methods in Molecular Biology

Volumn 686, Issue , 2011, Pages 429-446

  Su, Hua ^a   Yang, Guo Yuan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adeno associated virus; Astrocyte; Capillary density; Endothelial cells; Gene transfer; Ischemia; Middle cerebral artery occlusion; Neurons; VEGF

Indexed keywords

VASCULOTROPIN A;

ADENOVIRUS; ANIMAL; ARTICLE; BRAIN ISCHEMIA; CELL LINE; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; MOUSE;

ADENOVIRIDAE; ANIMALS; BRAIN ISCHEMIA; CELL LINE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 79957765704     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-938-3_22     Document Type: Chapter

References (67)

1. Weintraub M I (2006) Thrombolysis (tissue plasminogen activator) in stroke: a medicole-gal quagmire. Stroke 37, 1917–1922
2. Ohab JJ, Fleming S, Blesch A, Carmichael ST (2006) A neurovascular niche for neurogenesis after stroke. J Neurosci 26, 13007–13016
3. del Zoppo GJ (2006) Stroke and neurovascular protection. N Engl J Med 354, 553–555
4. McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5, 333–338
5. Leker RR, Soldner F, Velasco I, Gavin DK, Androutsellis-Theotokis A, McKay RD (2007) Long-lasting regeneration after ischemia in the cerebral cortex. Stroke 38, 153–161
6. Shen F, Su H, Liu W, Kan YW, Young WL, Yang GY (2006) Recombinant adeno-associated viral vector encoding human VEGF165 induces neomicrovessel formation in the adult mouse brain. Front Biosci 11, 3190–3198
7. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111, 1843–1851
8. Bellomo M, Adamo EB, Deodato B, Catania MA, Mannucci C, Marini H, Marciano MC, Marini R, Sapienza S, Giacca M, Caputi AP, Squadrito F, Calapai G (2003) Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil. Pharmacol Res 48, 309–317
9. Andsberg G, Kokaia Z, Klein RL, Muzyczka N, Lindvall O, Mandel R J (2002) Neuropathological and behavioral consequences of adeno-associated viral vector-mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model in rats. Neurobiol Dis 9, 187–204
10. Tsai TH, Chen SL, Chiang YH, Lin SZ, Ma H I, Kuo SW, Tsao YP (2000) Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage. Exp Neurol 166, 266–275
11. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM (1999) Gene therapy vectors based on adeno-associated virus type 1. J Virol 73, 3994–4003
12. Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, Briot D, Cherel Y, Chenuaud P, Samulski J, Moullier P, Rolling F (2003) Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after sub-retinal delivery. Mol Ther 7, 774–781
13. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA (2000) Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 74, 3852–3858
14. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97, 3428–3432
15. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE (2000) Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2, 619–623
16. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE (2001) Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 4, 217–222
17. Duan D, Yan Z, Yue Y, Ding W, Engelhardt JF (2001) Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol 75, 7662–7671
18. Braddock M (2005) Safely slowing down the decline in Alzheimer’s disease: gene therapy shows potential. Expert Opin Investig Drugs 14, 913–915
19. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11, 551–555
20. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, Shera D, Lioutermann L, Feely M, Freese A, Leone P (2006) Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 8, 577–588
21. Fulci G, Chiocca EA (2007) The status of gene therapy for brain tumors. Expert Opin Biol Ther 7, 197–208
22. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palu G (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12, 835–848
23. Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC, Rainov NG (2003) Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene–a phase I/II clinical protocol. J Neurooncol 64, 147–154
24. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11, 2389–2401
25. Chu Y, Miller JD, Heistad DD (2007) Gene therapy for stroke: 2006 overview. Curr Hypertens Rep 9, 19–24
26. Heistad DD (2006) Gene therapy for vascular disease. Vascul Pharmacol 45, 331–333
27. Hsich G, Sena-Esteves M, Breakefield XO (2002) Critical issues in gene therapy for neurologic disease. Hum Gene Ther 13, 579–604
28. Yenari MA, Dumas TC, Sapolsky RM, Steinberg GK (2001) Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors. Ann N Y Acad Sci 939, 340–357
29. Watanabe T, Okuda Y, Nonoguchi N, Zhao M Z, Kajimoto Y, Furutama D, Yukawa H, Shibata MA, Otsuki Y, Kuroiwa T, Miyatake S (2004) Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 24, 1205–1213
30. Shimamura M, Sato N, Oshima K, Aoki M, Kurinami H, Waguri S, Uchiyama,Y, Ogihara T, Kaneda Y, Morishita R (2004) Novel ther- apeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 109, 424–431
31. Li H, Qian ZM (2002) Transferrin/transfer-rin receptor-mediated drug delivery. Med Res Rev 22, 225–250
32. Pang L, Ye W, Che XM, Roessler BJ, Betz A L, Yang GY (2001) Reduction of inflammatory response in the mouse brain with adeno-viral-mediated transforming growth factor-ss1 expression. Stroke 32, 544–552
33. Hayashi K, Morishita R, Nakagami H, Yoshimura S, Hara A, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Sakai N (2001) Gene therapy for preventing neuronal death using hepatocyte growth factor: in vivo gene transfer of HGF to subarachnoid space prevents delayed neuronal death in gerbil hippocampal CA1 neurons. Gene Ther 8, 1167–1173
34. Yang GY, Mao Y, Zhou LF, Ye W, Liu XH, Gong C, Betz AL (1999) Attenuation of temporary focal cerebral ischemic injury in the mouse following transfection with interleukin-1 receptor antagonist. Brain Res Mol Brain Res 72, 129–137
35. Betz AL, Yang GY, Davidson BL (1995) Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 15, 547–551
36. Davis AS, Zhao H, Sun GH, Sapolsky RM, Steinberg GK (2007) Gene therapy using SOD1 protects striatal neurons from experimental stroke. Neurosci Lett 411, 32–36
37. Badin RA, Lythgoe MF, van der Weerd L, Thomas DL, Gadian DG, Latchman DS (2006) Neuroprotective effects of virally delivered HSPs in experimental stroke. J Cereb Blood Flow Metab 26, 371–381
38. Baker AH, Sica V, Work LM, Williams-Ignarro S, de Nigris F, Lerman LO, Casamassimi A, Lanza A, Schiano C, Rienzo M, Ignarro LJ, Napoli C (2007) Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proc Natl Acad Sci U S A 104, 3597–3602
39. Frampton AR Jr, Goins WF, Nakano K, Burton EA, Glorioso JC (2005) HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther 12, 891–901
40. Wang C, Wang CM, Clark KR, Sferra TJ (2003) Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther 10, 1528–1534
41. Xu DG, Crocker SJ, Doucet JP, St-Jean M, Tamai K, Hakim AM, Ikeda JE, Liston P, Thompson CS, Korneluk RG, MacKenzie A, Robertson GS (1997) Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med 3, 997–1004
42. Pechan PA, Yoshida T, Panahian N, Moskowitz MA, Breakefield XO (1995) Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat. Neuroreport 6, 669–672
43. Miao HS, Yu LY, Hui GZ, Guo LH (2005) Antiapoptotic effect both in vivo and in vitro of A20 gene when transfected into rat hippocampal neurons. Acta Pharmacol Sin 26, 33–38
44. Shirakura M, Fukumura M, Inoue M, Fujikawa S, Maeda M, Watabe K, Kyuwa S, Yoshikawa Y, Hasegawa M (2003) Sendai virus vector-mediated gene transfer of glial cell line-derived neurotrophic factor prevents delayed neuronal death after transient global ischemia in gerbils. Exp Anim 52, 119–127
45. Shen F, Su H, Fan Y-F, Zhu Y, Chen Y, Kan YW, Young WL, Yang GY (2006) Induction of focal angiogenesis through adeno-associated viral vector mediated VEGF165 gene transfer in the mature mouse brain (Abstract). Stroke 37, 685
46. Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Ishii K, Kobune M, Hirai S, Uchida H, Sasaki K, Ito Y, Kato K, Honmou O, Houkin K, Date I, Hamada H (2005) Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 11, 96–104
47. Gu W, Zhao H, Yenari MA, Sapolsky R M, Steinberg GK (2004) Catalase over-expression protects striatal neurons from transient focal cerebral ischemia. Neuroreport 15, 413–416
48. Hoehn B, Yenari MA, Sapolsky RM, Steinberg GK (2003) Glutathione peroxidase overexpression inhibits cytochrome C release and proapoptotic mediators to protect neurons from experimental stroke. Stroke 34, 2489–2494
49. Tsai TH, Chen SL, Xiao X, Chiang YH, Lin SZ, Kuo SW, Liu DW, Tsao YP (2003) Gene treatment of cerebral stroke by rAAV vector delivering IL-1ra in a rat model. Neuroreport 14, 803–807
50. Lawrence M S, McLaughlin JR, Sun GH, Ho DY, McIntosh L, Kunis DM, Sapolsky R M, Steinberg GK (1997) Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow Metab 17, 740–744
51. Zhao MZ, Nonoguchi N, Ikeda N, Watanabe T, Furutama D, Miyazawa D, Funakoshi H, Kajimoto Y, Nakamura T, Dezawa M, Shibata MA, Otsuki Y, Coffin RS, Liu WD, Kuroiwa T, Miyatake S (2006) Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab 26, 1176–1188
52. Sugiura S, Kitagawa K, Tanaka S, Todo K, Omura-Matsuoka E, Sasaki T, Mabuchi T, Matsushita K, Yagita Y, Hori M (2005) Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats. Stroke 36, 859–864
53. Sun Y, Jin K, Clark KR, Peel A, Mao XO, Chang Q, Simon RP, Greenberg DA (2003) Adeno-associated virus-mediated delivery of BCL-w gene improves outcome after transient focal cerebral ischemia. Gene Ther 10, 115–122
54. Hadaczek P, Kohutnicka M, Krauze MT, Bringas J, Pivirotto P, Cunningham J, Bankiewicz, K (2006) Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17, 291–302
55. Vilaboa N, Voellmy R (2006) Regulatable gene expression systems for gene therapy. Curr Gene Ther 6, 421–438
56. Yang GY, Zhao Y, Davidson BL, Betz AL (1997) Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 751, 181–188
57. Yang GY, Xu B, Hashimoto T, Huey M, Chaly T, Jr, Wen R, Young WL (2003) Induction of focal angiogenesis through adenoviral vector mediated vascular endothelial cell growth factor gene transfer in the mature mouse brain. Angiogenesis 6, 151–158
58. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL (2004) Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstim-ulation of vascular endothelial growth factor in a mouse model. Stroke 35, 1715–1719
59. Gao G P, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99, 11854–11859
60. Rutledge EA, Halbert CL, Russell DW (1998) Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 72, 309–319
61. Muramatsu S, Mizukami H, Young NS, Brown K E (1996) Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 221, 208–217
62. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM (1997) Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 71, 6823–6833
63. Chiorini JA, Kim F, Yang L, Kotin RM (1999) Cloning and characterization of adeno-associated virus type 5. J Virol 73, 1309–1319
64. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson S W, Thistlethwaite PA (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348, 500–509
65. Clark KR, Liu X, McGrath JP, Johnson PR (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 10, 1031–1039
66. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites,TJ Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ, Snyder RO (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158–167
67. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6, 973–985